TY - JOUR
T1 - Dose-dependent outcome of ebv infection of humanized mice based on green raji unit (Gru) doses
AU - Chen, Haiwen
AU - Zhong, Ling
AU - Zhang, Wanlin
AU - Zhang, Shanshan
AU - Hong, Junping
AU - Zhou, Xiang
AU - Zhang, Xinyu
AU - Feng, Qisheng
AU - Chen, Yixin
AU - Zeng, Yi Xin
AU - Xu, Miao
AU - Krummenacher, Claude
AU - Zhang, Xiao
N1 - Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021/11
Y1 - 2021/11
N2 - Humanized mouse models are used as comprehensive small-animal models of EBV infec-tion. Previously, infectious doses of EBV used in vivo have been determined mainly on the basis of TD50 (50% transforming dose), which is a time-consuming process. Here, we determined infectious doses of Akata-EBV-GFP using green Raji units (GRUs), and characterized dose-dependent effects in humanized mice. We defined two outcomes in vivo, including an infection model and a lymphoma model, following inoculation with low or high doses of Akata-EBV-GFP, respectively. Inoculation with a low dose induced primary B cells to become lymphoblastoid cell lines in vitro, and caused latent infection in humanized mice. In contrast, a high dose of Akata-EBV-GFP resulted in primary B cells death in vitro, and fatal B cell lymphomas in vivo. Following infection with high doses, the frequency of CD19+ B cells decreased, whereas the percentage of CD8+ T cells increased in peripheral blood and the spleen. At such doses, a small part of activated CD8+ T cells was EBV-specific CD8+ T cells. Thus, GRUs quantitation of Akata-EBV-GFP is an effective way to quantify infectious doses to study pathologies, immune response, and to assess (in vivo) the neutralizing activity of antibodies raised by immunization against EBV.
AB - Humanized mouse models are used as comprehensive small-animal models of EBV infec-tion. Previously, infectious doses of EBV used in vivo have been determined mainly on the basis of TD50 (50% transforming dose), which is a time-consuming process. Here, we determined infectious doses of Akata-EBV-GFP using green Raji units (GRUs), and characterized dose-dependent effects in humanized mice. We defined two outcomes in vivo, including an infection model and a lymphoma model, following inoculation with low or high doses of Akata-EBV-GFP, respectively. Inoculation with a low dose induced primary B cells to become lymphoblastoid cell lines in vitro, and caused latent infection in humanized mice. In contrast, a high dose of Akata-EBV-GFP resulted in primary B cells death in vitro, and fatal B cell lymphomas in vivo. Following infection with high doses, the frequency of CD19+ B cells decreased, whereas the percentage of CD8+ T cells increased in peripheral blood and the spleen. At such doses, a small part of activated CD8+ T cells was EBV-specific CD8+ T cells. Thus, GRUs quantitation of Akata-EBV-GFP is an effective way to quantify infectious doses to study pathologies, immune response, and to assess (in vivo) the neutralizing activity of antibodies raised by immunization against EBV.
UR - http://www.scopus.com/inward/record.url?scp=85118415064&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85118415064&partnerID=8YFLogxK
U2 - 10.3390/v13112184
DO - 10.3390/v13112184
M3 - Article
C2 - 34834989
AN - SCOPUS:85118415064
SN - 1999-4915
VL - 13
JO - Viruses
JF - Viruses
IS - 11
M1 - 2184
ER -